Daré Bioscience to Host First Quarter 2020 Financial Results and Company Update Conference Call and Webcast on May 14, 2020

Rhea-AI Summary

Daré Bioscience (NASDAQ: DARE) announced a conference call on May 14, 2020, at 4:30 p.m. ET to discuss Q1 2020 financial results and provide a company update. Investors can join the call by dialing (844) 831-3031 or through a live webcast available on their website. The company focuses on women's health innovations, with products in development including Ovaprene, Sildenafil Cream, DARE-BV1, and DARE-HRT1. The call will be accessible for replay until May 21, 2020.

Positive

• Conference call scheduled for May 14, 2020, to review Q1 financial results.
• Company continues to develop innovative women's health products.

Negative

• None.

SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, May 14, 2020, to review its financial results for the quarter ended March 31, 2020 and to provide a Company update.

To access the conference call via phone, dial (844) 831-3031 (U.S.) or (443) 637-1284 (international). The conference ID number for the call is 3387116. The live webcast can be accessed under “Events & Presentations" in the Investor Relations section of the Company's website at www.darebioscience.com. Please log in approximately 5-10 minutes prior to the call to register and to download and install any necessary software. To access the replay, please call (855) 859-2056 (U.S.) or (404) 537-3406 (international). The conference ID number for the replay is 3387116. The call and webcast replay will be available until May 21, 2020.

About Daré Bioscience

Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health, and fertility.

Daré’s product portfolio includes potential first-in-category candidates in clinical development: Ovaprene^®, a hormone-free, monthly contraceptive intravaginal ring whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra^®; DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis via a single application; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy following menopause. To learn more about Daré’s full portfolio of women’s health product candidates, and mission to deliver differentiated therapies for women, please visit www.darebioscience.com.

Daré may announce material information about its finances, product candidates, clinical trials and other matters using its investor relations website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts on its investor relations website (https://darebioscience.gcs-web.com/) and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted on the investor relations page of Daré’s website mentioned above.

Contacts:

Investors on behalf of Daré Bioscience, Inc.:
Lee Roth
Burns McClellan
lroth@burnsmc.com
212.213.0006

OR

Media on behalf of Daré Bioscience, Inc.:
Jake Robison
Canale Communications
jake@canalecomm.com
619.849.5383 

Source: Daré Bioscience

FAQ

When is Daré Bioscience's next conference call?

Daré Bioscience's next conference call is scheduled for May 14, 2020, at 4:30 p.m. ET.

How can I access the Daré Bioscience conference call?

The conference call can be accessed by phone at (844) 831-3031, or internationally at (443) 637-1284, and via live webcast on their website.

What is the focus of Daré Bioscience?

Daré Bioscience focuses on the advancement of innovative healthcare products for women, particularly in areas such as contraception, sexual health, and fertility.

What products is Daré Bioscience developing?

Daré Bioscience is developing several products including Ovaprene, Sildenafil Cream, DARE-BV1, and DARE-HRT1.

When will the replay of the Daré conference call be available?

The replay of the conference call will be available until May 21, 2020.